Outputs (78)

Laf4/Aff3, a Gene Involved in Intellectual Disability, Is Required for Cellular Migration in the Mouse Cerebral Cortex (2014)
Journal Article
Moore, J. M., Oliver, P. L., Finelli, M. J., Lee, S., Lickiss, T., Molnár, Z., & Davies, K. E. (2014). Laf4/Aff3, a Gene Involved in Intellectual Disability, Is Required for Cellular Migration in the Mouse Cerebral Cortex. PLoS ONE, 9(8), 1-11. https://doi.org/10.1371/journal.pone.0105933

Members of the AFF (AF4/FMR2) family of putative transcription factors are involved in infant acute leukaemia and intellectual disability (ID), although very little is known about their transcriptional targets. For example, deletion of human lymphoid... Read More about Laf4/Aff3, a Gene Involved in Intellectual Disability, Is Required for Cellular Migration in the Mouse Cerebral Cortex.

Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy (2014)
Journal Article
Albarakati, N., Abdel-Fatah, T. M., Doherty, R., Russell, R., Agarwal, D., Moseley, P., Perry, C., Arora, A., Alsubhi, N., Seedhouse, C., Rakha, E. A., Green, A., Ball, G., Chan, S., Caldas, C., Ellis, I. O., & Madhusudan, S. (2015). Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Molecular Oncology, 9(1), 204-217. https://doi.org/10.1016/j.molonc.2014.08.001

BRCA1, a key factor in homologous recombination (HR) repair may also regulate base excision repair (BER). Targeting BRCA1‐BER deficient cells by blockade of ATM and DNA‐PKcs could be a promising strategy in breast cancer. We investigated BRCA1, XRCC1... Read More about Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer (2014)
Journal Article
Rudraraju, B., Droog, M., Abdel-Fatah, T. M., Zwart, W., Giannoudis, A., Malki, M. I., Moore, D., Patel, H., Shaw, J., Ellis, I. O., Chan, S., Brooke, G. N., Nevedomskaya, E., Nigro, C. L., Carroll, J., Coombes, R. C., Bevan, C., Ali, S., & Palmieri, C. (2014). Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. Breast Cancer Research and Treatment, 147(2), 295-309. https://doi.org/10.1007/s10549-014-3098-0

Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia (2014)
Journal Article
Hulse, R., Beazley-Long, N., Hua, J., Kennedy, H., Prager, J., Bevan, H., Qiu, Y., Fernandes, E., Gammons, M., Ballmer-Hofer, K., Gittenberger de Groot, A., Churchill, A., Harper, S., Brain, S., Bates, D., & Donaldson, L. (2014). Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia. Neurobiology of Disease, 71, 245-259. https://doi.org/10.1016/j.nbd.2014.08.012

Vascular endothelial growth factor-A (VEGF-A) is best known as a key regulator of the formation of new blood vessels. Neutralization of VEGF-A with anti-VEGF therapy e.g. bevacizumab, can be painful, and this is hypothesized to result from a loss of... Read More about Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia.

Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance (2014)
Journal Article
Hamdollah Zadeh, M. A., Amin, E. M., Hoareau-Aveilla, C., Domingo, E., Symonds, K. E., Ye, X., Heesom, K. J., Salmon, A., D'Silva, O., Betteridge, K. B., Williams, A. C., Kerr, D. J., Salmon, A. H., Oltean, S., Midgley, R. S., Ladomery, M. R., Harper, S. J., Varey, A. H., & Bates, D. O. (2015). Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance. Molecular Oncology, 9(1), 167-178. https://doi.org/10.1016/j.molonc.2014.07.017

Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity (2014)
Journal Article
Bates, D., Ngo, D. T. M., Farb, M. G., Kikuchi, R., Karki, S., Tiwari, S., Bigornia, S. J., LaValley, M. P., Hamburg, N. M., Vita, J. A., Hess, D. T., Walsh, K., & Gokce, N. (2014). Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity. Circulation, 130(13), 1072-1080. https://doi.org/10.1161/CIRCULATIONAHA.113.008171

Background—Experimental studies suggest that visceral adiposity and adipose tissue dysfunction play a central role in obesity-related cardiometabolic complications. Impaired angiogenesis in fat has been implicated in the development of adipose tissue... Read More about Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity.

Methods for assessing the regenerative responses of neural tissue (2014)
Book Chapter
Poser, S. W., Rueger, M. A., & Androutsellis-Theotokis, A. (2014). Methods for assessing the regenerative responses of neural tissue. In B. Christ, J. Oerlecke, & P. Stock (Eds.), Animal models for stem cell therapy (293-302). Humana Press. https://doi.org/10.1007/978-1-4939-1453-1_24

In order to establish novel therapeutic paradigms and advance the field of regenerative medicine, methods for their effective implementation as well as rigorous assessment of outcomes are critical. This is especially evident and challenging in the co... Read More about Methods for assessing the regenerative responses of neural tissue.

ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer (2014)
Journal Article
Jerjees, D. A., Alabdullah, M., Alkaabi, M., Abduljabbar, R., Muftah, A., Nolan, C., Green, A. R., Ellis, I. O., & Rakha, E. A. (2014). ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer. Breast Cancer Research and Treatment, 147(1), 25-37. https://doi.org/10.1007/s10549-014-3066-8

The extracellular-regulated kinase (ERK) 1/2 is one of the members of the mitogen-activated protein kinases (MAPKs). MAPKs are transduction proteins that play a role in controlling diverse cellular functions including proliferation and survival. In b... Read More about ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer.

Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma (2014)
Journal Article
Motzer, R. J., Barrios, C. H., Min Kim, T., Falcon, S., Cosgriff, T., Graydon Harker, W., Srimuninnimit, V., Pittman, K., Sabbatini, R., Young Rha, S., Flaig, T. W., Page, R., Bavbek, S., Thaddeus Beck, J., Patel, P., Cheung, F.-Y., Yadav, S., Schiff, E. M., Wang, X., Niolat, J., …Knox, J. J. (2014). Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 32(25), 2765-2772. https://doi.org/10.1200/JCO.2013.54.6911

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma (2014)
Journal Article
Gammons, M., Lucas, R., Dean, R., Coupland, S., Oltean, S., & Bates, D. (2014). Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. British Journal of Cancer, 111(3), 477-485. https://doi.org/10.1038/bjc.2014.342